Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

April 30, 2009

Conditions
HIV Infections
Interventions
DRUG

Optimized Background Therapy (OBT)

OBT (3-6 drugs based on treatment history and resistance testing)

DRUG

maraviroc (UK-427,857)

maraviroc (UK-427,857) 150 mg taken once daily

DRUG

Optimized Background Therapy (OBT)

OBT (3-6 drugs based on treatment history and resistance testing)

DRUG

maraviroc (UK-427,857)

maraviroc (UK-427,857) 150 mg taken twice daily

DRUG

Optimized Background Therapy (OBT)

OBT (3-6 drugs based on treatment history and resistance testing)

Trial Locations (77)

1000

Pfizer Investigational Site, Brussels

1070

Pfizer Investigational Site, Brussels

1200

Pfizer Investigational Site, Brussels

2010

Pfizer Investigational Site, Darlinghurst

Pfizer Investigational Site, Surry Hills

3004

Pfizer Investigational Site, Melbourne

3053

Pfizer Investigational Site, Carlton

4000

Pfizer Investigational Site, Liège

4029

Pfizer Investigational Site, Herston

8091

Pfizer Investigational Site, Zurich

10018

Pfizer Investigational Site, New York

10461

Pfizer Investigational Site, The Bronx

10467

Pfizer Investigational Site, The Bronx

11030

Pfizer Investigational Site, Manhasset

11203

Pfizer Investigational Site, Brooklyn

11794

Pfizer Investigational Site, Stony Brook

12157

Pfizer Investigational Site, Berlin

12208

Pfizer Investigational Site, Albany

14004

Pfizer Investigational Site, Córdoba

19106

Pfizer Investigational Site, Philadelphia

19130

Pfizer Investigational Site, Philadelphia

20009

Pfizer Investigational Site, Washington D.C.

20036

Pfizer Investigational Site, Washington D.C.

20099

Pfizer Investigational Site, Hamburg

20146

Pfizer Investigational Site, Hamburg

20246

Pfizer Investigational Site, Hamburg

22003

Pfizer Investigational Site, Annandale

28006

Pfizer Investigational Site, Madrid

28046

Pfizer Investigational Site, Madrid

28078

Pfizer Investigational Site, Huntersville

29206

Pfizer Investigational Site, Columbia

30308

Pfizer Investigational Site, Atlanta

32803

Pfizer Investigational Site, Orlando

32806

Pfizer Investigational Site, Orlando

32960

Pfizer Investigational Site, Vero Beach

33133

Pfizer Investigational Site, Miami

33169

Pfizer Investigational Site, North Miami Beach

33614

Pfizer Investigational Site, Tampa

34243

Pfizer Investigational Site, Sarasota

35294

Pfizer Investigational Site, Birmingham

50924

Pfizer Investigational Site, Cologne

75204

Pfizer Investigational Site, Dallas

75246

Pfizer Investigational Site, Dallas

85006

Pfizer Investigational Site, Phoenix

87505

Pfizer Investigational Site, Santa Fe

90027

Pfizer Investigational Site, Los Angeles

90028

Pfizer Investigational Site, Los Angeles

90069

Pfizer Investigational Site, Los Angeles

90211

Pfizer Investigational Site, Beverly Hills

92663

Pfizer Investigational Site, Newport Beach

92708

Pfizer Investigational Site, Fountain Valley

94102

Pfizer Investigational Site, San Francisco

94118

Pfizer Investigational Site, San Francisco

94545

Pfizer Investigational Site, Hayward

94587

Pfizer Investigational Site, Union City

94602

Pfizer Investigational Site, Oakland

98372

Pfizer Investigational Site, Puyallup

98405

Pfizer Investigational Site, Tacoma

98664

Pfizer Investigational Site, Vancouver

94115-1931

Pfizer Investigational Site, San Francisco

01107

Pfizer Investigational Site, Springfield

11794-7310

Pfizer Investigational Site, Stony Brook

R3A 1R9

Pfizer Investigational Site, Winnipeg

M5B 1W8

Pfizer Investigational Site, Toronto

M5G 2N2

Pfizer Investigational Site, Toronto

H2L 4P9

Pfizer Investigational Site, Montreal

H2L 5B1

Pfizer Investigational Site, Montreal

H2X 2P4

Pfizer Investigational Site, Montreal

H3G 1A4

Pfizer Investigational Site, Montreal

3584 CX

Pfizer Investigational Site, Utrecht

03202

Pfizer Investigational Site, Elche

08916

Pfizer Investigational Site, Badalona

08025

Pfizer Investigational Site, Barcelona

BN2 1ES

Pfizer Investigational Site, Brighton

EH4 2XU

Pfizer Investigational Site, Edinburgh

SE5 9RS

Pfizer Investigational Site, London

SW10 9TH

Pfizer Investigational Site, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT00098748 - Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects | Biotech Hunter | Biotech Hunter